Unnatural Selection
By Ralph Brave,
Baltimore City Paper
| 06. 21. 2000
Any day now, the Rockville-based Celera Genomics Group and
the National Institutes of Health will announce that they have achieved a feat
unique in all of history, one that will alter the destiny of all humanity for
all time to come: the decoding of the entire human genome, the 3 billion or so
units of DNA in every cell in the human body--the code of human life in all its
variety.
The effort of thousands of people and the expenditure of billions of dollars
have gone into the making of this epochal moment, but when it occurs it will
belong above all others to James Watson--first director of the federal
government’s Human Genome Project, the pioneering biochemist whose work
uncovering the double-helix structure of DNA made the project possible. Thus it
is only fitting that Watson provide the invocation for any effort to understand
the meaning of this miracle. Here, then, is James Watson on the awesome
responsibility of assuming stewardship over the sacred stuff of life itself:
“Evolution can be just damn cruel, and to say that we’ve got...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...